Literature DB >> 12558359

Hepatitis C in the HIV-Infected Person.

Mark S Sulkowski1, David L Thomas.   

Abstract

Because of shared routes of transmission, hepatitis C virus (HCV) infection is common in HIV-infected persons, who have been experiencing increasing HCV-related morbidity and mortality since the advent of effective antiretroviral therapy. Infection with HIV appears to adversely affect the outcome of hepatitis C, leading to increased viral persistence after acute infection, higher levels of viremia, and accelerated progression of HCV-related liver disease. In addition, hepatitis C may affect the course and management of HIV infection. The medical management of hepatitis C in HIV-infected persons is complicated by immune suppression, potential drug interactions and toxicities, and other forms of liver disease. In addition, there is little published experience with the safety and efficacy of the best available anti-HCV medications in HIV-infected persons. Thus, current efforts must be directed at preventing HCV and HIV infections and applying the principles learned in treating persons with either infection to manage those with both. Future efforts should include studies of the pathogenesis of HCV infection in HIV-infected persons and large, prospective studies that demonstrate the optimal management of persons co-infected with HIV and HCV. Such efforts will help to eliminate HCV-related liver disease as an emerging threat to HIV-infected persons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558359     DOI: 10.7326/0003-4819-138-3-200302040-00012

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  113 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

2.  HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group.

Authors:  Kevin P High; Mark Brennan-Ing; David B Clifford; Mardge H Cohen; Judith Currier; Steven G Deeks; Sherry Deren; Rita B Effros; Kelly Gebo; Jörg J Goronzy; Amy C Justice; Alan Landay; Jules Levin; Paolo G Miotti; Robert J Munk; Heidi Nass; Charles R Rinaldo; Michael G Shlipak; Russell Tracy; Victor Valcour; David E Vance; Jeremy D Walston; Paul Volberding
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

3.  Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults.

Authors:  Judith I Tsui; Debbie M Cheng; Howard Libman; Carly Bridden; Jeffrey Samet
Journal:  AIDS Care       Date:  2012-01-24

4.  Felt and enacted stigma among HIV/HCV-coinfected adults: the impact of stigma layering.

Authors:  Helen-Maria Lekas; Karolynn Siegel; Jason Leider
Journal:  Qual Health Res       Date:  2011-04-15

5.  Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens.

Authors:  E Kainne Dokubo; Jennifer Evans; Valerie Winkelman; Sherri Cyrus; Leslie H Tobler; Alice Asher; Alya Briceno; Kimberly Page
Journal:  J Clin Virol       Date:  2014-01-27       Impact factor: 3.168

6.  Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.

Authors:  Monica A Konerman; Shruti H Mehta; Catherine G Sutcliffe; Trang Vu; Yvonne Higgins; Michael S Torbenson; Richard D Moore; David L Thomas; Mark S Sulkowski
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

7.  Hepatitis C Virus Treatment in HIV-Coinfected Patients: No Longer Different From Monoinfection Treatment.

Authors:  Bevin Hearn; David Delbello; Joseph Lawler; Michel Ng; Alyson Harty; Douglas T Dieterich
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-11

8.  Pharmacokinetics and safety of boosted elvitegravir in subjects with hepatic impairment.

Authors:  Joseph M Custodio; Martin Rhee; Gong Shen; Kah Hiing J Ling; Brian P Kearney; Srinivasan Ramanathan
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening.

Authors:  R Irvin; A McAdams-Mahmoud; D Hickman; J Wilson; W Fenwick; I Chen; N Irvin; O Falade-Nwulia; M Sulkowski; R Chaisson; D L Thomas; S H Mehta
Journal:  J Community Med Health Educ       Date:  2016-05-30

10.  Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria.

Authors:  Ogbodo Ekene Newton; Otue Akpevwe Oghene; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.